Fasting Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® Tablets 250 mg
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's terbinafine
hydrochloride 250 mg tablets to Novartis' Lamisil® 250 mg tablets following a single, oral
250 mg (1 x 250 mg) dose administered under fasting conditions.